The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Favipiravir Market Research Report 2024
Synopsis
Favipiravir, sold under the brand name Avigan, is an antiviral medication used to treat influenza in Japan. It is also being studied to treat a number of other viral infections. Like the experimental antiviral drugs (T-1105 and T-1106), it is a pyrazinecarboxamide derivative. It is being developed and manufactured by Toyama Chemical (Fujifilm group) and was approved for medical use in Japan in 2014. In 2016, Fujifilm licensend API for it to Zhejiang Hisun Pharmaceutical Co. of China. It became a generic drug in 2019.
The global Favipiravir market was valued at US$ 342.8 million in 2023 and is anticipated to reach US$ 11 million by 2030, witnessing a CAGR of -22.0% during the forecast period 2024-2030.
In the global Favipiravir market, ChemRar Group, Glenmark, Fujifilm, Dr. Reddy, R-Pharma are the key players. The global 5 Largest Favipiravir Players account for 70% market share by revenue. India hold a key market revenue share of the Favipiravir market which account for 73%. The classification of Favipiravir includes Brand Drug and Generic Drug. Brand Drug accounted for a share of 16% in the global Favipiravir market. Favipiravir is widely used for Influenza Viruses, COVID-19, etc. The most proportion of Favipiravir is used for COVID-19 and the proportion is 97%.
This report aims to provide a comprehensive presentation of the global market for Favipiravir, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Favipiravir.
Report Scope
The Favipiravir market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Favipiravir market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Favipiravir manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
ChemRar Group
Glenmark
Fujifilm
Dr. Reddy
R-Pharma
Cipla
Lupin
Sun Pharma
Hisun Pharm
Segment by Type
Brand Drug
Generic Drug
Segment by Application
Influenza Viruses
COVID-19
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Favipiravir manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Favipiravir in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Favipiravir, sold under the brand name Avigan, is an antiviral medication used to treat influenza in Japan. It is also being studied to treat a number of other viral infections. Like the experimental antiviral drugs (T-1105 and T-1106), it is a pyrazinecarboxamide derivative. It is being developed and manufactured by Toyama Chemical (Fujifilm group) and was approved for medical use in Japan in 2014. In 2016, Fujifilm licensend API for it to Zhejiang Hisun Pharmaceutical Co. of China. It became a generic drug in 2019.
The global Favipiravir market was valued at US$ 342.8 million in 2023 and is anticipated to reach US$ 11 million by 2030, witnessing a CAGR of -22.0% during the forecast period 2024-2030.
In the global Favipiravir market, ChemRar Group, Glenmark, Fujifilm, Dr. Reddy, R-Pharma are the key players. The global 5 Largest Favipiravir Players account for 70% market share by revenue. India hold a key market revenue share of the Favipiravir market which account for 73%. The classification of Favipiravir includes Brand Drug and Generic Drug. Brand Drug accounted for a share of 16% in the global Favipiravir market. Favipiravir is widely used for Influenza Viruses, COVID-19, etc. The most proportion of Favipiravir is used for COVID-19 and the proportion is 97%.
This report aims to provide a comprehensive presentation of the global market for Favipiravir, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Favipiravir.
Report Scope
The Favipiravir market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Favipiravir market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Favipiravir manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
ChemRar Group
Glenmark
Fujifilm
Dr. Reddy
R-Pharma
Cipla
Lupin
Sun Pharma
Hisun Pharm
Segment by Type
Brand Drug
Generic Drug
Segment by Application
Influenza Viruses
COVID-19
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Favipiravir manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Favipiravir in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Favipiravir Market Overview
1.1 Product Overview and Scope of Favipiravir
1.2 Favipiravir Segment by Type
1.2.1 Global Favipiravir Market Value Comparison by Type (2024-2030)
1.2.2 Brand Drug
1.2.3 Generic Drug
1.3 Favipiravir Segment by Application
1.3.1 Global Favipiravir Market Value by Application: (2024-2030)
1.3.2 Influenza Viruses
1.3.3 COVID-19
1.3.4 Others
1.4 Global Favipiravir Market Size Estimates and Forecasts
1.4.1 Global Favipiravir Revenue 2019-2030
1.4.2 Global Favipiravir Sales 2019-2030
1.4.3 Global Favipiravir Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Favipiravir Market Competition by Manufacturers
2.1 Global Favipiravir Sales Market Share by Manufacturers (2019-2024)
2.2 Global Favipiravir Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Favipiravir Average Price by Manufacturers (2019-2024)
2.4 Global Favipiravir Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Favipiravir, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Favipiravir, Product Type & Application
2.7 Favipiravir Market Competitive Situation and Trends
2.7.1 Favipiravir Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Favipiravir Players Market Share by Revenue
2.7.3 Global Favipiravir Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Favipiravir Retrospective Market Scenario by Region
3.1 Global Favipiravir Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Favipiravir Global Favipiravir Sales by Region: 2019-2030
3.2.1 Global Favipiravir Sales by Region: 2019-2024
3.2.2 Global Favipiravir Sales by Region: 2025-2030
3.3 Global Favipiravir Global Favipiravir Revenue by Region: 2019-2030
3.3.1 Global Favipiravir Revenue by Region: 2019-2024
3.3.2 Global Favipiravir Revenue by Region: 2025-2030
3.4 North America Favipiravir Market Facts & Figures by Country
3.4.1 North America Favipiravir Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Favipiravir Sales by Country (2019-2030)
3.4.3 North America Favipiravir Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Favipiravir Market Facts & Figures by Country
3.5.1 Europe Favipiravir Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Favipiravir Sales by Country (2019-2030)
3.5.3 Europe Favipiravir Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Favipiravir Market Facts & Figures by Country
3.6.1 Asia Pacific Favipiravir Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Favipiravir Sales by Country (2019-2030)
3.6.3 Asia Pacific Favipiravir Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Favipiravir Market Facts & Figures by Country
3.7.1 Latin America Favipiravir Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Favipiravir Sales by Country (2019-2030)
3.7.3 Latin America Favipiravir Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Favipiravir Market Facts & Figures by Country
3.8.1 Middle East and Africa Favipiravir Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Favipiravir Sales by Country (2019-2030)
3.8.3 Middle East and Africa Favipiravir Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Favipiravir Sales by Type (2019-2030)
4.1.1 Global Favipiravir Sales by Type (2019-2024)
4.1.2 Global Favipiravir Sales by Type (2025-2030)
4.1.3 Global Favipiravir Sales Market Share by Type (2019-2030)
4.2 Global Favipiravir Revenue by Type (2019-2030)
4.2.1 Global Favipiravir Revenue by Type (2019-2024)
4.2.2 Global Favipiravir Revenue by Type (2025-2030)
4.2.3 Global Favipiravir Revenue Market Share by Type (2019-2030)
4.3 Global Favipiravir Price by Type (2019-2030)
5 Segment by Application
5.1 Global Favipiravir Sales by Application (2019-2030)
5.1.1 Global Favipiravir Sales by Application (2019-2024)
5.1.2 Global Favipiravir Sales by Application (2025-2030)
5.1.3 Global Favipiravir Sales Market Share by Application (2019-2030)
5.2 Global Favipiravir Revenue by Application (2019-2030)
5.2.1 Global Favipiravir Revenue by Application (2019-2024)
5.2.2 Global Favipiravir Revenue by Application (2025-2030)
5.2.3 Global Favipiravir Revenue Market Share by Application (2019-2030)
5.3 Global Favipiravir Price by Application (2019-2030)
6 Key Companies Profiled
6.1 ChemRar Group
6.1.1 ChemRar Group Corporation Information
6.1.2 ChemRar Group Description and Business Overview
6.1.3 ChemRar Group Favipiravir Sales, Revenue and Gross Margin (2019-2024)
6.1.4 ChemRar Group Favipiravir Product Portfolio
6.1.5 ChemRar Group Recent Developments/Updates
6.2 Glenmark
6.2.1 Glenmark Corporation Information
6.2.2 Glenmark Description and Business Overview
6.2.3 Glenmark Favipiravir Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Glenmark Favipiravir Product Portfolio
6.2.5 Glenmark Recent Developments/Updates
6.3 Fujifilm
6.3.1 Fujifilm Corporation Information
6.3.2 Fujifilm Description and Business Overview
6.3.3 Fujifilm Favipiravir Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Fujifilm Favipiravir Product Portfolio
6.3.5 Fujifilm Recent Developments/Updates
6.4 Dr. Reddy
6.4.1 Dr. Reddy Corporation Information
6.4.2 Dr. Reddy Description and Business Overview
6.4.3 Dr. Reddy Favipiravir Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Dr. Reddy Favipiravir Product Portfolio
6.4.5 Dr. Reddy Recent Developments/Updates
6.5 R-Pharma
6.5.1 R-Pharma Corporation Information
6.5.2 R-Pharma Description and Business Overview
6.5.3 R-Pharma Favipiravir Sales, Revenue and Gross Margin (2019-2024)
6.5.4 R-Pharma Favipiravir Product Portfolio
6.5.5 R-Pharma Recent Developments/Updates
6.6 Cipla
6.6.1 Cipla Corporation Information
6.6.2 Cipla Description and Business Overview
6.6.3 Cipla Favipiravir Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Cipla Favipiravir Product Portfolio
6.6.5 Cipla Recent Developments/Updates
6.7 Lupin
6.6.1 Lupin Corporation Information
6.6.2 Lupin Description and Business Overview
6.6.3 Lupin Favipiravir Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Lupin Favipiravir Product Portfolio
6.7.5 Lupin Recent Developments/Updates
6.8 Sun Pharma
6.8.1 Sun Pharma Corporation Information
6.8.2 Sun Pharma Description and Business Overview
6.8.3 Sun Pharma Favipiravir Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Sun Pharma Favipiravir Product Portfolio
6.8.5 Sun Pharma Recent Developments/Updates
6.9 Hisun Pharm
6.9.1 Hisun Pharm Corporation Information
6.9.2 Hisun Pharm Description and Business Overview
6.9.3 Hisun Pharm Favipiravir Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Hisun Pharm Favipiravir Product Portfolio
6.9.5 Hisun Pharm Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Favipiravir Industry Chain Analysis
7.2 Favipiravir Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Favipiravir Production Mode & Process
7.4 Favipiravir Sales and Marketing
7.4.1 Favipiravir Sales Channels
7.4.2 Favipiravir Distributors
7.5 Favipiravir Customers
8 Favipiravir Market Dynamics
8.1 Favipiravir Industry Trends
8.2 Favipiravir Market Drivers
8.3 Favipiravir Market Challenges
8.4 Favipiravir Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
